16 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 1, 7 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 7 | Completed 4, Terminated 2, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Altimmune, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH Pemvidutide, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 3 | Recruiting | Altimmune, Inc. | 1800 | 2026-07-30 | 2026-09-23 |
| RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) Pemvidutide, Placebo - Alcohol-associated Liver Disease | Phase 2 | Active not recruiting | Altimmune, Inc. | 121 | 2025-06-16 | 2026-08-17 |
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Pemvidutide, Placebo - Alcohol Use Disorder (AUD) | Phase 2 | Completed | Altimmune, Inc. | 100 | 2025-05-15 | 2026-07-31 |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) Pemvidutide, Placebo - Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Altimmune, Inc. | 212 | 2023-07-27 | 2026-05-18 |
| Efficacy and Safety of ALT-801 in the Treatment of Obesity ALT-801, Placebo - Obesity/Overweight | Phase 2 | Completed | Altimmune, Inc. | 391 | 2022-03-31 | 2023-11-29 |
| Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) ALT-801, Placebo - Non-Alcoholic Fatty Liver Disease | Phase 1 | Completed | Altimmune, Inc. | 64 | 2022-03-09 | 2023-07-27 |
| ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) ALT-801, Placebo - Type 2 Diabetes | Phase 1 | Completed | Altimmune, Inc. | 55 | 2022-02-01 | 2025-06-24 |
| ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) ALT-801, Placebo - Non-Alcoholic Fatty Liver Disease | Phase 1 | Completed | Altimmune, Inc. | 95 | 2021-09-30 | 2023-07-27 |
| Pemvidutide (ALT-801) DDI Study in Healthy Volunteers Pemvidutide, Metformin, Atorvastatin - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Altimmune, Inc. | 40 | 2021-09-15 | 2025-06-24 |
| Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) AdCOVID, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 92 | 2021-02-25 | 2023-08-14 |
| HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) HepTcell, Placebo - Hepatitis B, Chronic | Phase 2 | Terminated | Altimmune, Inc. | 87 | 2020-12-26 | 2025-12-08 |
| ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability ALT-801, Placebo - Obesity, Nonalcoholic Steatohepatitis | Phase 1 | Completed | Altimmune, Inc. | 100 | 2020-11-10 | 2025-06-24 |
| NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) NasoVAX, Placebo - Coronavirus Infection | Phase 2 | Terminated | Altimmune, Inc. | 48 | 2020-10-10 | 2022-04-04 |
| NasoShield in Healthy Adults to Study Safety and Immunogenicity NasoShield, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 43 | 2020-06-15 | 2025-06-24 |
| Study of the Safety and Immunogenicity of NasoVAX Extension Subjects were administered NasoVAX high dose - Influenza | Completed | Altimmune, Inc. | 8 | 2019-01-21 | 2025-06-19 | |
| NasoShield Study of Safety and Immunogenicity NasoShield, BioThrax, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 145 | 2018-01-18 | 2025-06-24 |
| Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX NasoVAX - Influenza | Phase 2 | Completed | Altimmune, Inc. | 60 | 2017-09-18 | 2024-04-30 |
| Immune Response Following Seasonal Influenza Vaccination Licensed seasonal influenza vaccine - Influenza | Phase 4 | Completed | Altimmune, Inc. | 20 | 2017-05-08 | 2019-04-26 |
| Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B FP-02.2 Vaccine, Placebo, IC31® Adjuvant - Hepatitis B | Phase 1 | Completed | Altimmune, Inc. | 61 | 2015-07-01 | 2025-05-22 |
| Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. Pandemic Influenza Vaccine, Placebo - Influenza A Subtype H5N1 Infection | Phase 1 | Completed | Altimmune, Inc. | 48 | 2008-10-01 | 2025-05-29 |
Obesity (6) · Non-alcoholic Fatty Liver Disease (5) · Overweight (5) · Influenza, Human (4) · Anthrax (2) · COVID-19 (2) · Alcoholism (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 2 (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Influenza in Birds (1)
ALT-801 (6) · Atorvastatin (1) · Biothrax (1) · Digoxin (1) · Ethinyl Estradiol (1) · Levonorgestrel (1) · Metformin (1) · Warfarin (1)
United States (17) · Australia (3) · Puerto Rico (2) · United Kingdom (2) · Canada (1) · Germany (1) · South Korea (1) · Spain (1)
Sarah K Browne, MD (3) · Emanuel DeNoia, MD (1) · M. Scott Harris, MD (1) · Mark Thursz, MD (1) · Peta-Gay Jackson-Booth, MD (1) · Scott D. Parker, M.D. (1) · Stephan Bart, MD (1) · Stephen Bart, MD (1)